Patent: 7,329,642
✉ Email this page to a colleague
Summary for Patent: 7,329,642
Title: | .beta.-2-glycoprotein is an inhibitor of angiogenesis |
Abstract: | The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked .beta.2-Glycoprotein 1 (.beta.2GP1) to cells associated with the tissue. The presence of .beta.2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides a method for treating tumors by providing .beta.2GP1 to the tumor. |
Inventor(s): | Schroit; Alan Jay (Bellaire, TX), Balasubramanian; Krishnakumar (Pearland, TX), McCarty; Marya (Houston, TX) |
Assignee: | Board of Regents, University of Texas System (Austin, TX) |
Application Number: | 10/406,158 |
Patent Claims: | see list of patent claims |
Details for Patent 7,329,642
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2022-05-17 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2022-05-17 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2022-05-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |